Edesa Biotech, Inc.
As of Oct 22, 2026, Edesa Biotech is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $2.76, 84.9% below its 52-week high and below its 200-day average, which is rising.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is EDSA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
EDSA among Biotechnology183rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …183 | EDSA | Stage 4 · wk 6 | 56 | −30.5% |
Edesa Biotech: quick answers
What stage is Edesa Biotech in?
As of Oct 22, 2026, Edesa Biotech (EDSA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Edesa Biotech in an uptrend?
No. Edesa Biotech is in a Stage 4 downtrend. It trades 50.9% below its 200-day average, which is rising.
How far is Edesa Biotech from its 52-week high?
Edesa Biotech closed at $2.76 on Oct 22, 2026, 84.9% below its 52-week high of $18.28. Its 52-week low is $0.80.
How has Edesa Biotech performed over the past year?
As of Oct 22, 2026, Edesa Biotech is up 1.8% over the past year and up 84.0% so far in 2026.
Which sector and industry is Edesa Biotech in?
Edesa Biotech is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.